Additionally, research into IGF2BP3’s role in ovarian cancer (OC) identifies the small molecule AE-848, which disrupts IGF2BP3’s interaction with target mRNAs, leading to decreased levels of factors like c-MYC, VEGF, and CDK2. Here, IGF2BP3 is linked to ovarian carcinoma.